A Phase I/II Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)
Latest Information Update: 18 Apr 2025
At a glance
- Drugs Capecitabine (Primary) ; CDX 1140 (Primary) ; Oxaliplatin (Primary) ; Pembrolizumab (Primary)
- Indications Biliary cancer; Carcinoma
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 15 Apr 2025 Status changed from suspended to recruiting.
- 08 Apr 2025 Status changed from recruiting to suspended.
- 06 May 2024 Planned initiation date(estimated date of recruitment of the first subject) changed to 12 May 2024.